Dr. Wendy Huang, CEO of Lumosa Therapeutics, received the 2015 National Innovation Award today (12/24) on behalf of Lumosa team at W Hotel, Taipei, from Mr. Jin-pyng Wang, the Speaker of the Taiwan Legislative Yuan (Congress), for the development of LT1001 (Naldebain™，SDE), the first long-acting intramuscular analgesic injection. LT1001 features an extended release formulation which provides up to 7-day analgesic effect, low side effects, and low risk of addiction. The product is designed to effectively elevate patient quality of life and reduce burden of healthcare professionals. This award not only recognized the development and the technical capabilities of Lumosa team, but also encouraged those who were involved in the project. Lumosa is looking forward to achieve another great milestone when LT1001 is approved for marketing in the future.